Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 1,045.3% in May

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 330,345 shares, an increase of 1,045.3% from the May 14th total of 28,844 shares. Approximately 21.2% of the shares of the company are short sold. Based on an average daily trading volume, of 3,203,228 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Stock Performance

AEMD traded down $0.09 on Tuesday, reaching $1.94. The company had a trading volume of 135,568 shares, compared to its average volume of 1,627,829. The business has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $2.51. The company has a market cap of $3.05 million, a price-to-earnings ratio of -0.13 and a beta of 1.49. Aethlon Medical has a 52-week low of $1.36 and a 52-week high of $27.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.